About MabVax
MabVax is a publicly listed company based in San Diego (United States) founded in 2006. It operates as a human monoclonal antibodies and vaccines for the diagnosis and treatment of various cancers. MabVax has raised $20.98 million across 17 funding rounds from investors including HHS, Opko Health and National Cancer Institute. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
MabVax Therapeutics engages in the discovery development of proprietary human monoclonal antibody products and vaccines for the diagnosis and treatment of various cancers. It has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines are targeting recurrent sarcoma and ovarian cancer and a vaccine to address the orphan disease neuroblastoma has completed an initial Phase I trial at MSKCC, as well as completed an additional Phase I vaccine clinical trials in melanoma, ovarian cancer, breast cancer, and small cell lung cancer. The companys product candidates include 5B1 antibody program, 5B1 imaging program, and 5B1 antibody-drug conjugate, which target antigens over expressed on metastatic pancreatic, colon, stomach, ovarian, breast, and small cell lung cancers.
- Headquarters San Diego, United States
- Stage Public
- SectorsHealthcare
- Website mabvax.com
- Social LinkedIn X
- Total Equity Funding$20.98M (USD)
in 17 rounds
- Latest Funding Round$830K (USD), Post-IPO
Apr 2018
- InvestorsHHS
& 5 more
Funding Insights of MabVax
MabVax has successfully raised a total of $20.98M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $830 thousand completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.98M
- Total Rounds 17
- Last Round Post-IPO — $830,000
- First Round $1.1M
(Apr 2007)
- Investors Count 6
Latest 10 of 17 funding rounds of MabVax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $830,000 | Post-IPO | – | – | – |
| Feb 2018 | $2.75M | Post-IPO | – | – | – |
| Aug 2017 | $1.3M | Post-IPO | – | – | – |
| Jan 2016 | $5M | Debt – Conventional | – | – | – |
| Apr 2015 | $11.61M | Post-IPO | – | – | |
| Jul 2014 | $3.04M | Series C | – | – | – |
| Feb 2014 | $12.05M | Series C | – | – | – |
| Nov 2012 | $5.25M | Series B | – | Numoda Capital Innovations | |
| Jul 2012 | $149,152 | Grant | – | – | |
| Apr 2011 | $1.85M | Grant | – | – |
6 investors in total: 6 institutional.
Investors in MabVax
MabVax has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Opko Health and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | numodacapital.com | - | |
Venture capital firm focused on early-stage technology companies | 2011 | rtp.vc | New York, United States | |
Molecular diagnostic products for prostate cancer assessment are provided. | 1991 | opko.com | Miami, United States | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Cancer research is conducted and supported by the institute. | – | cancer.gov | Bethesda, United States |
Investor details for MabVax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MabVax
1 people are tracked at MabVax (1 in leadership).
| Name | Role | Group |
|---|---|---|
David Hansen | President and CEO | Leadership |
Complete people profiles for MabVax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MabVax
4 dated milestones of MabVax across 12 years, from founding to its latest funding, stage changes and deals.
- Founded MabVax is founded.
- Funding First funding round of $1.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $830K.
Competitors of MabVax
MabVax has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of MabVax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MabVax
Websites that share an audience with MabVax (mabvax.com).
Websites whose visitors overlap most with MabVax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| inovio.com | 100% | 11.7K | #1,670,423 | View details | |
amgentrials.com | amgentrials.com | 99% | – | #6,144,055 | – |
| appliedclinicaltrialsonline.com | 99% | – | #747,616 | View details | |
| nmcancercenter.org | 63% | – | #2,509,467 | View details | |
cancer.unm.edu | cancer.unm.edu | 62% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for MabVax
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as MabVax (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mabvax
Complete news archive for MabVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MabVax
MabVax was founded in 2006 and raised its 1st funding round 1 year after it was founded.
MabVax is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
MabVax is a funded company, having raised a total of $20.98M across 17 funding rounds to date. The company's 1st funding round was a Grant of $1.85M, raised on Apr 2007.
MabVax Therapeutics engages in the discovery development of proprietary human monoclonal antibody products and vaccines for the diagnosis and treatment of various cancers. It has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines are targeting recurrent sarcoma and ovarian cancer and a vaccine to address the orphan disease neuroblastoma has completed an initial Phase I trial at MSKCC, as well as completed an additional Phase I vaccine clinical trials in melanoma, ovarian cancer, breast cancer, and small cell lung cancer. The companys product candidates include 5B1 antibody program, 5B1 imaging program, and 5B1 antibody-drug conjugate, which target antigens over expressed on metastatic pancreatic, colon, stomach, ovarian, breast, and small cell lung cancers.
MabVax's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
MabVax has 6 investors. Key investors include HHS, Opko Health, National Cancer Institute, RTP Global, and Burrill and Company.